Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT-EXT open-label extension of odevixibat in Alagille syndrome
NL-OMON54015Phase 3Not yet recruiting
- Sponsor
- Albireo Pharma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Albireo Pharma. Primary endpoint: Change from baseline in scratching through Week 72. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NL-OMON54015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54015.